Thyroid stunning in vivo and in vitro

Nuclear Medicine Communications

Volumn 26, Issue 8, 2005, Pages 731-735

  Medvedec, Mario ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Dosimetry; Radioiodine therapy; Thyroid cancer; Thyroid disease; Thyroid stunning

Indexed keywords

IODINE 131;

ARTICLE; COMPARATIVE STUDY; DOSIMETRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; RADIATION DOSE; RADIOISOTOPE THERAPY; THYROID CANCER; THYROID CELL;

BODY BURDEN; CELL LINE, TUMOR; HUMANS; IODINE RADIOISOTOPES; RADIATION INJURIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; RELATIVE BIOLOGICAL EFFECTIVENESS; RISK ASSESSMENT; RISK FACTORS; THYROID GLAND; THYROID NEOPLASMS;

EID: 23044478811     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000169380.92270.73     Document Type: Article

References (12)

1. Rawson RW, Rall JE, Peacock W. Limitations and indications in the treatment of cancer of the thyroid with radioactive iodine. J Clin Endocrinol Metab 1951; 11:1128-1142.
2. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 1986; 13:277-279.
3. Medvedec M. Do we read carefully? Eur J Nucl Med Mol Imaging 2003; 30:475-476.
4. Kalinyak JE, McDougall IR. Whole-body scanning with radionuclides of iodine, and the controversy of ‘thyroid stunning’. Nucl Med Commun 2004; 25:883-889.
5. Medvedec M, Grosev D, Loncaric S, Pavlinovic Z, Dodig D. Thyroid stunning: full-quantitative approach based on radiation absorbed dose analysis. Eur J Nucl Med 2000; 27:923.
6. Sabri O, Zimny M, Schreckenberger M, Meyer-Oelmann A, Reinartz P, Buell U. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med 2000; 27:1591-1597.
7. Sinyuta B, Dzhuzha D. The influence of diagnostic radiation absorbed dose and time interval on the degree of thyroid stunning. Eur J Nucl Med 2001; 28:1004.
8. Behr TM, Schipper ML, Gotthardt M, Gratz S, Hoeffken H, Behe MP. Factors influencing the therapeutic outcome of radioiodine therapy in differentiated thyroid cancer (DTC): do we really need stimulated TSH levels. Eur J Nucl Med Mol Imaging 2002; 29:S308.
9. Postgard P, Himmelman J, Lindencrona U, Bhogal N, Wiberg D, Berg G, et al. Stunning of iodide transport by I-131 irradiation in cultured thyroid epithelial cells. J Nucl Med 2002; 43:828-834.
10. Lassmann M, Luster M, Haenshied H, Reiners C. Impact of I-131 diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004; 45:619-625.
11. Hall EJ. Radiation dose-rate: a factor of importance in radiobiology and radiotherapy. Br J Radiol 1972; 45:81-97.
12. Medvedec M, Grosev D, Loncaric S, Dodig D. Hold the threshold. Eur J Nucl Med Mol Imaging 2004; 31:S466.